These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23725668)

  • 1. Bacteriophage-host interaction: from splendid isolation into a messy reality.
    Brüssow H
    Curr Opin Microbiol; 2013 Aug; 16(4):500-6. PubMed ID: 23725668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dispersing biofilms with engineered enzymatic bacteriophage.
    Lu TK; Collins JJ
    Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11197-202. PubMed ID: 17592147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three New Escherichia coli Phages from the Human Gut Show Promising Potential for Phage Therapy.
    Dalmasso M; Strain R; Neve H; Franz CM; Cousin FJ; Ross RP; Hill C
    PLoS One; 2016; 11(6):e0156773. PubMed ID: 27280590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteriophage isolated from feedlot cattle can reduce Escherichia coli O157:H7 populations in ruminant gastrointestinal tracts.
    Callaway TR; Edrington TS; Brabban AD; Anderson RC; Rossman ML; Engler MJ; Carr MA; Genovese KJ; Keen JE; Looper ML; Kutter EM; Nisbet DJ
    Foodborne Pathog Dis; 2008 Apr; 5(2):183-91. PubMed ID: 18407757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-even-related bacteriophages as candidates for treatment of Escherichia coli urinary tract infections.
    Nishikawa H; Yasuda M; Uchiyama J; Rashel M; Maeda Y; Takemura I; Sugihara S; Ujihara T; Shimizu Y; Shuin T; Matsuzaki S
    Arch Virol; 2008; 153(3):507-15. PubMed ID: 18188500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy.
    Chibani-Chennoufi S; Sidoti J; Bruttin A; Kutter E; Sarker S; Brüssow H
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2558-69. PubMed ID: 15215109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a broad host range lytic bacteriophage against E. coli adhered to urothelium.
    Sillankorva S; Oliveira D; Moura A; Henriques M; Faustino A; Nicolau A; Azeredo J
    Curr Microbiol; 2011 Apr; 62(4):1128-32. PubMed ID: 21140149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bacteriophage cocktail targeting Escherichia coli reduces E. coli in simulated gut conditions, while preserving a non-targeted representative commensal normal microbiota.
    Cieplak T; Soffer N; Sulakvelidze A; Nielsen DS
    Gut Microbes; 2018; 9(5):391-399. PubMed ID: 29517960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of lytic bacteriophages in the prevention and eradication of biofilms of Proteus mirabilis and Escherichia coli.
    Carson L; Gorman SP; Gilmore BF
    FEMS Immunol Med Microbiol; 2010 Aug; 59(3):447-55. PubMed ID: 20528927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro.
    Ryan EM; Alkawareek MY; Donnelly RF; Gilmore BF
    FEMS Immunol Med Microbiol; 2012 Jul; 65(2):395-8. PubMed ID: 22524448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploiting gut bacteriophages for human health.
    Dalmasso M; Hill C; Ross RP
    Trends Microbiol; 2014 Jul; 22(7):399-405. PubMed ID: 24656964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Spatial Heterogeneity of the Gut Limits Predation and Fosters Coexistence of Bacteria and Bacteriophages.
    Lourenço M; Chaffringeon L; Lamy-Besnier Q; Pédron T; Campagne P; Eberl C; Bérard M; Stecher B; Debarbieux L; De Sordi L
    Cell Host Microbe; 2020 Sep; 28(3):390-401.e5. PubMed ID: 32615090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of phages on two-species bacterial communities.
    Harcombe WR; Bull JJ
    Appl Environ Microbiol; 2005 Sep; 71(9):5254-9. PubMed ID: 16151111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of Escherichia coli-bacteriophage interactions by surfactants and antibiotics in vitro.
    Scanlan PD; Bischofberger AM; Hall AR
    FEMS Microbiol Ecol; 2017 Jan; 93(1):. PubMed ID: 27737900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing biofilms of clinically relevant organisms using bacteriophage.
    Donlan RM
    Trends Microbiol; 2009 Feb; 17(2):66-72. PubMed ID: 19162482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Phage infection of populations of motile bacteria as a model for the study of virus resistance of multicellular systems with heterogeneous growth cycle phases].
    Medvinskiĭ AB; Fishov IL; Tsyganov AM; Ivanitskiĭ GR
    Dokl Akad Nauk SSSR; 1990; 311(6):1479-81. PubMed ID: 2209395
    [No Abstract]   [Full Text] [Related]  

  • 17. Phage therapy: the Escherichia coli experience.
    Brüssow H
    Microbiology (Reading); 2005 Jul; 151(Pt 7):2133-2140. PubMed ID: 16000704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy.
    Ryan EM; Gorman SP; Donnelly RF; Gilmore BF
    J Pharm Pharmacol; 2011 Oct; 63(10):1253-64. PubMed ID: 21899540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic use of phage cocktail for controlling Escherichia coli O157:H7 in gastrointestinal tract of mice.
    Tanji Y; Shimada T; Fukudomi H; Miyanaga K; Nakai Y; Unno H
    J Biosci Bioeng; 2005 Sep; 100(3):280-7. PubMed ID: 16243277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmid profile, colicinogeny and phage sensitivity as indicators of the dynamics of Escherichia coli populations in the human gut.
    Burova LM; Korneichuk EP; Kushkina AI; Tovkach FI
    Mikrobiol Z; 2012; 74(5):99-107. PubMed ID: 23120990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.